Media Advisory: Experts Available to Discuss Historic Cancer Drug Approval

Today, for the first time, a drug has been FDA-approved for cancer based on disease genetics rather than type. Developed from 30 years of basic research at Johns Hopkins and its Bloomberg~Kimmel Institute, pembroluzimab now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in so-called mismatch repair genes.


Current News Releases

Submit comment

Allowed HTML tags: <a href="http://google.com">google</a> <strong>bold</strong> <em>emphasized</em> <code>code</code> <blockquote>
quote
</blockquote>